Open AccessLack of response to octreotide in Cushing's syndrome due to metastatic adrenocortical carcinoma
Author(s) -
N N Chan,
A J Isaacs
Publication year - 1999
Publication title -
postgraduate medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.568
H-Index - 99
eISSN - 1469-0756
pISSN - 0032-5473
DOI - 10.1136/pgmj.75.880.96
Subject(s) - medicine , adrenocortical carcinoma , octreotide , somatostatin , cushing syndrome , metyrapone , chemotherapy , mitotane , carcinoma , neuroendocrine carcinoma , metastatic carcinoma , oncology , endocrinology
Functional metastatic adrenocortical carcinoma is an uncommon cause of Cushing's syndrome, which rarely responds to conventional treatment. A patient presenting with Cushing's syndrome secondary to adrenocortical carcinoma underwent surgical resection. Postoperatively, she developed metastatic disease resistant to conventional chemotherapy. Octreotide, a somatostatin analogue which is effective in the treatment of several types of neuroendocrine tumour, was tried to ameliorate her secretory symptoms, but without any therapeutic effect.